Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 17.73 USD 3.74% Market Closed
Market Cap: 1.9B USD
Have any thoughts about
Novocure Ltd?
Write Note
NVCR
/
Balance Sheet
/
Cash Equivalents

Novocure Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Novocure Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Novocure Ltd
NASDAQ:NVCR
Cash Equivalents
$171.7m
CAGR 3-Years
-36%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Novocure Ltd
Glance View

Market Cap
1.9B USD
Industry
Health Care

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

NVCR Intrinsic Value
24.31 USD
Undervaluation 27%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Novocure Ltd's Cash Equivalents?
Cash Equivalents
171.7m USD

Based on the financial report for Sep 30, 2024, Novocure Ltd's Cash Equivalents amounts to 171.7m USD.

What is Novocure Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-3%

Over the last year, the Cash Equivalents growth was 22%. The average annual Cash Equivalents growth rates for Novocure Ltd have been -36% over the past three years , -3% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.